Savara (NASDAQ:SVRA) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Savara (NASDAQ:SVRA) issued its quarterly earnings results on Wednesday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01), FiscalAI reports.

Savara Price Performance

SVRA traded down $0.05 during trading on Thursday, reaching $5.23. 177,665 shares of the stock were exchanged, compared to its average volume of 1,500,243. The company has a debt-to-equity ratio of 0.15, a current ratio of 11.85 and a quick ratio of 11.85. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -9.33 and a beta of 0.28. Savara has a 1 year low of $1.89 and a 1 year high of $7.01. The business’s 50 day moving average price is $5.37 and its two-hundred day moving average price is $5.48.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Wall Street Zen lowered Savara from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. Oppenheimer assumed coverage on Savara in a report on Friday, April 24th. They issued an “outperform” rating and a $11.00 price target for the company. HC Wainwright restated a “buy” rating on shares of Savara in a research note on Monday, March 16th. William Blair set a $10.00 price objective on Savara in a report on Monday, March 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $9.13.

Institutional Investors Weigh In On Savara

Several institutional investors and hedge funds have recently made changes to their positions in the business. RTW Investments LP purchased a new position in Savara during the 4th quarter valued at about $35,893,000. VR Adviser LLC grew its position in shares of Savara by 172.7% in the second quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock valued at $20,256,000 after purchasing an additional 5,626,624 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Savara in the fourth quarter valued at approximately $27,496,000. Perceptive Advisors LLC purchased a new position in shares of Savara during the 4th quarter worth approximately $14,472,000. Finally, State Street Corp raised its position in shares of Savara by 83.6% during the 4th quarter. State Street Corp now owns 4,333,022 shares of the company’s stock worth $26,128,000 after purchasing an additional 1,973,164 shares during the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.